SCHEDULE: AQR Capital Management Reports Stake in Vanda Pharmaceuticals

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported beneficial ownership of 5.82% of Vanda Pharmaceuticals Inc. common stock as of June 30, 2026.

Summary

• AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed a Schedule 13G, indicating their beneficial ownership of Vanda Pharmaceuticals Inc. common stock.
• As of June 30, 2026, the reporting entities collectively beneficially owned 3,497,695 shares, representing 5.82% of the class.
• The filing specifies shared voting power and shared dispositive power for these shares.
• Both entities are organized in the United States.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without disclosing specific strategic actions or financial performance updates.

Positives

• Significant institutional investor presence indicated by AQR Capital Management's stake.
• The filing is routine and provides transparency regarding ownership.

Negatives

• No specific financial performance or strategic updates are provided in this filing.
• The filing does not offer insights into the reasons for acquiring or holding the stake.

Risks

• Potential for increased market activity or volatility if AQR Capital Management adjusts its stake.
• Dependence on the investment strategies and decisions of AQR Capital Management.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Vanda Pharmaceuticals Inc.'s future performance. It solely reports on beneficial ownership.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that the filing of a Schedule 13G by AQR Capital Management, a prominent quantitative investment firm, indicates a significant institutional interest in Vanda Pharmaceuticals. This type of filing is common when an institutional investor crosses a 5% ownership threshold, signaling a passive investment approach unless otherwise stated.

Stakeholder Impact

• Shareholders: May observe increased institutional interest, potentially influencing stock liquidity and price discovery. The passive nature of the filing suggests no immediate intent to control the company.
• Management: Will be aware of a significant institutional holder, which could influence future strategic discussions or shareholder engagement.
• Creditors: No direct impact indicated by this filing.

Next Steps

• AQR Capital Management will continue to hold or adjust its position in Vanda Pharmaceuticals Inc. common stock.
• Vanda Pharmaceuticals Inc. will continue its business operations as disclosed in its other filings.

Key Dates

Keywords

Vanda Pharmaceuticals, AQR Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Securities Exchange Act